Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,096 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of ruxolitinib therapy on the quality-of-life of Japanese patients with myelofibrosis.
Oritani K, Ohishi K, Okamoto S, Kirito K, Komatsu N, Tauchi T, Handa H, Saito S, Takenaka K, Shimoda K, Okada H, Amagasaki T, Wakase S, Shimozuma K, Akashi K. Oritani K, et al. Among authors: okamoto s. Curr Med Res Opin. 2018 Mar;34(3):531-537. doi: 10.1080/03007995.2017.1415874. Epub 2018 Jan 4. Curr Med Res Opin. 2018. PMID: 29224367
Multicenter prospective trial evaluating the tolerability of imatinib for Japanese patients with chronic myelogenous leukemia in the chronic phase: does body weight matter?
Kanda Y, Okamoto S, Tauchi T, Kizaki M, Inokuchi K, Yabe M, Yokoyama K, Ito Y, Kimura Y, Higashihara M, Bessho M, Ando K, Chiba S, Kurokawa M, Oshimi K, Dan K, Ohyashiki K, Ikeda Y; Tokyo STI Study Group (TSSG). Kanda Y, et al. Among authors: okamoto s. Am J Hematol. 2008 Nov;83(11):835-9. doi: 10.1002/ajh.21274. Am J Hematol. 2008. PMID: 18785644 Free article. Clinical Trial.
A Phase I/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL.
Tojo A, Usuki K, Urabe A, Maeda Y, Kobayashi Y, Jinnai I, Ohyashiki K, Nishimura M, Kawaguchi T, Tanaka H, Miyamura K, Miyazaki Y, Hughes T, Branford S, Okamoto S, Ishikawa J, Okada M, Usui N, Tanii H, Amagasaki T, Natori H, Naoe T. Tojo A, et al. Among authors: okamoto s. Int J Hematol. 2009 Jun;89(5):679-88. doi: 10.1007/s12185-009-0327-0. Epub 2009 May 19. Int J Hematol. 2009. PMID: 19449194 Clinical Trial.
Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a double-blind, randomized Phase III clinical trial.
Shirasugi Y, Ando K, Miyazaki K, Tomiyama Y, Okamoto S, Kurokawa M, Kirito K, Yonemura Y, Mori S, Usuki K, Iwato K, Hashino S, Wei H, Lizambri R. Shirasugi Y, et al. Among authors: okamoto s. Int J Hematol. 2011 Jul;94(1):71-80. doi: 10.1007/s12185-011-0886-8. Epub 2011 Jun 25. Int J Hematol. 2011. PMID: 21706145 Clinical Trial.
Efficacy and safety of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL: a 36-month analysis of a phase I and II study.
Usuki K, Tojo A, Maeda Y, Kobayashi Y, Matsuda A, Ohyashiki K, Nakaseko C, Kawaguchi T, Tanaka H, Miyamura K, Miyazaki Y, Okamoto S, Oritani K, Okada M, Usui N, Nagai T, Amagasaki T, Wanajo A, Naoe T. Usuki K, et al. Among authors: okamoto s. Int J Hematol. 2012 Apr;95(4):409-19. doi: 10.1007/s12185-012-1026-9. Epub 2012 Feb 23. Int J Hematol. 2012. PMID: 22359103 Clinical Trial.
An open-label extension study evaluating the safety and efficacy of romiplostim for up to 3.5 years in thrombocytopenic Japanese patients with immune thrombocytopenic purpura (ITP).
Shirasugi Y, Ando K, Miyazaki K, Tomiyama Y, Iwato K, Okamoto S, Kurokawa M, Kirito K, Hashino S, Ninomiya H, Mori S, Yonemura Y, Usuki K, Wei H, Lizambri R. Shirasugi Y, et al. Among authors: okamoto s. Int J Hematol. 2012 Jun;95(6):652-9. doi: 10.1007/s12185-012-1065-2. Epub 2012 Apr 25. Int J Hematol. 2012. PMID: 22532046 Clinical Trial.
Efficacy and safety of ruxolitinib in Asian patients with myelofibrosis.
Jung CW, Shih LY, Xiao Z, Jie J, Hou HA, Du X, Wang MC, Park S, Eom KS, Oritani K, Okamoto S, Tauchi T, Kim JS, Zhou D, Saito S, Li J, Handa H, Jianyong L, Ohishi K, Hou M, Depei W, Takenaka K, Liu T, Hu Y, Amagasaki T, Ito K, Gopalakrishna P, Akashi K. Jung CW, et al. Among authors: okamoto s. Leuk Lymphoma. 2015 Jul;56(7):2067-74. doi: 10.3109/10428194.2014.969260. Epub 2014 Nov 20. Leuk Lymphoma. 2015. PMID: 25315076 Clinical Trial.
3,096 results